3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Lymphoma, Large B-Cell, Diffuse
36
Multiple Myeloma
33
Burkitt Lymphoma
32
Lymphoma
30
Leukemia, Myeloid, Acute
29
Lymphoma, Non-Hodgkin
28
Recurrence
26
Breast Neoplasms
26
Lymphoma, B-Cell
23
Neoplasms
22
Myelodysplastic Syndromes
20
Lymphoma, Follicular
20
Leukemia, Lymphocytic, Chronic, B-Cell
20
Hodgkin Disease
17
Triple Negative Breast Neoplasms
16
Leukemia
16
Ovarian Neoplasms
15
Hematologic Neoplasms
15
Melanoma
14
Neuroblastoma
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Mantle-Cell
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Pancreatic Neoplasms
11
Leukemia, Biphenotypic, Acute
10
Sarcoma
9
Neoplasm Metastasis
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myelomonocytic, Chronic
9
Interventions
fludarabine
1
Cyclophosphamide
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymic epithelial tumor
×
Cyclophosphamide
×
90 days
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled